Pilot phase I/II personalized therapy trial for metastatic colorectal cancer

Evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab

M. Pierobon, A. Silvestri, Alexander Spira, A. Reeder, E. Pin, S. Banks, Erika Parasido, K. Edmiston, L. Liotta, E. Petricoin

Research output: Contribution to journalArticle

Abstract

This nonrandomized phase I/II trial assessed the efficacy/tolerability of imatinib plus panitumumab in patients affected by metastatic colorectal cancer (mCRC) after stratification to treatment by selection of activated imatinib drug targets using reverse-phase protein array (RPPA). mCRC patients presenting with a biopsiable liver metastasis were enrolled. Allocation to the experimental and control arms was established using functional pathway activation mapping of c-Kit, PDGFR, and c-Abl phosphorylation by RPPA. The experimental arm received run-in escalation therapy with imatinib followed by panitumumab. The control arm received panitumumab alone. Seven patients were enrolled in the study. For three of the seven patients, sequential pre- and post-treatment biopsies were used to evaluate the effect of the therapeutic compounds on the drug targets and substrates. A decrease in the activation level of the drug targets and downstream substrates was observed in two of three patients. Combination therapy increased the activation of the AKT-mTOR pathway and several receptor tyrosine kinases. This study proposes a novel methodology for stratifying patients to personalized treatment based on the activation level of the drug targets. This workflow provides the ability to monitor changes in the signaling pathways after the administration of targeted therapies and to identify compensatory mechanisms.

Original languageEnglish (US)
Pages (from-to)2846-2855
Number of pages10
JournalJournal of Proteome Research
Volume13
Issue number6
DOIs
StatePublished - Jun 6 2014
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Chemical activation
Pharmaceutical Preparations
Proteins
Protein Array Analysis
Phosphorylation
Biopsy
Receptor Protein-Tyrosine Kinases
Substrates
Therapeutics
Liver
Workflow
Therapeutic Uses
panitumumab
Imatinib Mesylate
Neoplasm Metastasis

Keywords

  • chemoresistance
  • clinical trial
  • Colorectal cancer
  • individualized treatment
  • liver metastasis
  • reverse-phase protein microarray

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)
  • Medicine(all)

Cite this

Pilot phase I/II personalized therapy trial for metastatic colorectal cancer : Evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. / Pierobon, M.; Silvestri, A.; Spira, Alexander; Reeder, A.; Pin, E.; Banks, S.; Parasido, Erika; Edmiston, K.; Liotta, L.; Petricoin, E.

In: Journal of Proteome Research, Vol. 13, No. 6, 06.06.2014, p. 2846-2855.

Research output: Contribution to journalArticle

Pierobon, M. ; Silvestri, A. ; Spira, Alexander ; Reeder, A. ; Pin, E. ; Banks, S. ; Parasido, Erika ; Edmiston, K. ; Liotta, L. ; Petricoin, E. / Pilot phase I/II personalized therapy trial for metastatic colorectal cancer : Evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. In: Journal of Proteome Research. 2014 ; Vol. 13, No. 6. pp. 2846-2855.
@article{064554ce6788409fbac17df4ead52db5,
title = "Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: Evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab",
abstract = "This nonrandomized phase I/II trial assessed the efficacy/tolerability of imatinib plus panitumumab in patients affected by metastatic colorectal cancer (mCRC) after stratification to treatment by selection of activated imatinib drug targets using reverse-phase protein array (RPPA). mCRC patients presenting with a biopsiable liver metastasis were enrolled. Allocation to the experimental and control arms was established using functional pathway activation mapping of c-Kit, PDGFR, and c-Abl phosphorylation by RPPA. The experimental arm received run-in escalation therapy with imatinib followed by panitumumab. The control arm received panitumumab alone. Seven patients were enrolled in the study. For three of the seven patients, sequential pre- and post-treatment biopsies were used to evaluate the effect of the therapeutic compounds on the drug targets and substrates. A decrease in the activation level of the drug targets and downstream substrates was observed in two of three patients. Combination therapy increased the activation of the AKT-mTOR pathway and several receptor tyrosine kinases. This study proposes a novel methodology for stratifying patients to personalized treatment based on the activation level of the drug targets. This workflow provides the ability to monitor changes in the signaling pathways after the administration of targeted therapies and to identify compensatory mechanisms.",
keywords = "chemoresistance, clinical trial, Colorectal cancer, individualized treatment, liver metastasis, reverse-phase protein microarray",
author = "M. Pierobon and A. Silvestri and Alexander Spira and A. Reeder and E. Pin and S. Banks and Erika Parasido and K. Edmiston and L. Liotta and E. Petricoin",
year = "2014",
month = "6",
day = "6",
doi = "10.1021/pr401267m",
language = "English (US)",
volume = "13",
pages = "2846--2855",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Pilot phase I/II personalized therapy trial for metastatic colorectal cancer

T2 - Evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab

AU - Pierobon, M.

AU - Silvestri, A.

AU - Spira, Alexander

AU - Reeder, A.

AU - Pin, E.

AU - Banks, S.

AU - Parasido, Erika

AU - Edmiston, K.

AU - Liotta, L.

AU - Petricoin, E.

PY - 2014/6/6

Y1 - 2014/6/6

N2 - This nonrandomized phase I/II trial assessed the efficacy/tolerability of imatinib plus panitumumab in patients affected by metastatic colorectal cancer (mCRC) after stratification to treatment by selection of activated imatinib drug targets using reverse-phase protein array (RPPA). mCRC patients presenting with a biopsiable liver metastasis were enrolled. Allocation to the experimental and control arms was established using functional pathway activation mapping of c-Kit, PDGFR, and c-Abl phosphorylation by RPPA. The experimental arm received run-in escalation therapy with imatinib followed by panitumumab. The control arm received panitumumab alone. Seven patients were enrolled in the study. For three of the seven patients, sequential pre- and post-treatment biopsies were used to evaluate the effect of the therapeutic compounds on the drug targets and substrates. A decrease in the activation level of the drug targets and downstream substrates was observed in two of three patients. Combination therapy increased the activation of the AKT-mTOR pathway and several receptor tyrosine kinases. This study proposes a novel methodology for stratifying patients to personalized treatment based on the activation level of the drug targets. This workflow provides the ability to monitor changes in the signaling pathways after the administration of targeted therapies and to identify compensatory mechanisms.

AB - This nonrandomized phase I/II trial assessed the efficacy/tolerability of imatinib plus panitumumab in patients affected by metastatic colorectal cancer (mCRC) after stratification to treatment by selection of activated imatinib drug targets using reverse-phase protein array (RPPA). mCRC patients presenting with a biopsiable liver metastasis were enrolled. Allocation to the experimental and control arms was established using functional pathway activation mapping of c-Kit, PDGFR, and c-Abl phosphorylation by RPPA. The experimental arm received run-in escalation therapy with imatinib followed by panitumumab. The control arm received panitumumab alone. Seven patients were enrolled in the study. For three of the seven patients, sequential pre- and post-treatment biopsies were used to evaluate the effect of the therapeutic compounds on the drug targets and substrates. A decrease in the activation level of the drug targets and downstream substrates was observed in two of three patients. Combination therapy increased the activation of the AKT-mTOR pathway and several receptor tyrosine kinases. This study proposes a novel methodology for stratifying patients to personalized treatment based on the activation level of the drug targets. This workflow provides the ability to monitor changes in the signaling pathways after the administration of targeted therapies and to identify compensatory mechanisms.

KW - chemoresistance

KW - clinical trial

KW - Colorectal cancer

KW - individualized treatment

KW - liver metastasis

KW - reverse-phase protein microarray

UR - http://www.scopus.com/inward/record.url?scp=84902105414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902105414&partnerID=8YFLogxK

U2 - 10.1021/pr401267m

DO - 10.1021/pr401267m

M3 - Article

VL - 13

SP - 2846

EP - 2855

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 6

ER -